戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                             The risk for any adverse birth outcome was lower among infants exposed fr
2 ng 2005 to 2010 and estimated PTBs and other adverse birth outcomes for infants borne by non-Hispanic
3 esidential area, showing that an increase in adverse birth outcomes is observed with very high levels
4 ing factors, such as substance use, previous adverse birth outcomes, and demographic factors.
5 cidence of malaria, parasite prevalence, and adverse birth outcomes.
6 cal associations between arginine intake and adverse birth outcomes.
7                                        Major adverse cardiac and cardiovascular event rate at 30 days
8                            In-hospital major adverse cardiac and cerebral events occurred in 2.0% in
9  disease in the MM population as well as the adverse cardiac and vascular effects of MM itself.
10 his study recorded the occurrence of a major adverse cardiac event (MACE) assessed as the composite o
11 o significant differences in composite major adverse cardiac event scores at each time point up to 48
12 total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78)
13 n strategy with respect to the rate of major adverse cardiac events at 12 months.
14              The primary end point was major adverse cardiac events defined as all-cause mortality, h
15                                        Major adverse cardiac events occurred in 1.1% and 4.2% of ever
16 end points included clinical outcomes (major adverse cardiac events), use of healthcare resources, an
17 ional potential to counteract the effects of adverse cardiac remodeling, thereby improving survival a
18       The primary safety end point was major adverse cardiac, cerebrovascular, and renal events at 1
19  of systemic atherosclerosis with associated adverse cardiovascular and limb events.
20            Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial i
21 owed for incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-
22 ess than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted ha
23 ary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during th
24 e, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incide
25 the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality,
26  to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vas
27 sis is to compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI
28            Secondary outcomes included major adverse cardiovascular events.
29 diovascular risk factors at target and major adverse cardiovascular outcomes among patients with T1DM
30 s are independent and additive predictors of adverse cardiovascular outcomes in coronary artery disea
31           Myocardial fibrosis is linked with adverse clinical outcomes in adults after tetralogy of F
32 ks to its ability to resist and adapt to the adverse conditions it encounters upon infection.
33  inactive in the germ-line precursors during adverse conditions.
34 eptors may inadvertently produce substantial adverse consequences for cocaine addiction.
35 ther PAC can successfully compensate for the adverse consequences of a complicated postoperative reco
36 st have little chance of inducing unintended adverse consequences.
37  se and not merely by association with other adverse cytogenetic features.
38 assays have demonstrated an association with adverse disease outcomes, such as urethritis or nongonoc
39 ion of genetic variants associated with this adverse drug reaction will further our mechanistic under
40 ams was used to assess treatment completion, adverse drug reactions, and factors associated with trea
41 duced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to
42 r HO-CDI rates; this highlights an important adverse effect of the PIP/TAZO shortage and the importan
43 n turnover in ATM-depleted cells also has an adverse effect on the DNA base excision repair pathway,
44                              The most common adverse effect was decreased blood calcium (68.9% vs 59.
45 hich clozapine may act to cause this serious adverse effect.
46 ir therapeutic effects (analgesia) and their adverse effects (addiction and overdose).
47  achieving statistically significantly lower adverse effects (change in breast appearance [p=0.007 fo
48 t, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast rad
49 AES may exert context-specific beneficial or adverse effects in patients with critical illness.
50                           We observe similar adverse effects in sanitation, shelter, and health care
51 A1 ubiquitin-deficient mutants inhibited the adverse effects of Abeta on the surface expression of AM
52                             Furthermore, the adverse effects of ATB2 cells on glucose homeostasis wer
53                 None of the studies reported adverse effects of C. asiatica.
54 rotect human health and the environment from adverse effects of mercury.
55                                        These adverse effects of tPA were ameliorated in PPK (Klkb1)-d
56                     Steroid hormones produce adverse effects on biota as well as bioaccumulation in f
57                                  Obesity has adverse effects on cardiovascular hemodynamics and cardi
58  and maintenance resulted in initially small adverse effects on consumers, but ultimately led to popu
59  for the effects of sildenafil that, through adverse effects on mitochondrial function and endoplasmi
60 vioral tests showed no significant long-term adverse effects on sciatic nerve functions.
61  The 6 week long stimulation had no residual adverse effects on the electrophysiologic characteristic
62 s and may contribute toward infusion-related adverse effects such as allergic responses.
63 one of the key players in diabetes-mediating adverse effects to the neuronal and vascular components
64 ose used for recombination induction, caused adverse effects to the testis and to the reproductive en
65 ts; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis
66 d NK cells after haploidentical HSCT without adverse effects, increased GVHD, or higher mortality, an
67 , without any clear signal of any unexpected adverse effects.
68 elagolix were associated with hypoestrogenic adverse effects.
69 ding key information to limit immune-related adverse effects.
70 igh-dose prednisolone with potentially fewer adverse effects.
71 ectiveness, as well as clinical outcomes and adverse effects.
72 ng mortality rates, neurologic outcomes, and adverse effects.
73 % to 29% of patients reported opioid-induced adverse effects.
74 is needed to assess longer-term efficacy and adverse effects.
75 r dystrophy but are accompanied by prominent adverse effects.
76 um, which exhibits excellent adaptability to adverse environments, K(+) concentration remains at a re
77 hat dictates cell fate following exposure to adverse environments.
78                        At least one emergent adverse event (AE) was recorded for 79/190 (41x6%) in th
79 lpatasvir-voxilaprevir therapy because of an adverse event (AE).
80         Overall, 71% of patients suffered an adverse event (AE); the majority of these were grades 1
81 tional cohort study, we compared time to any adverse event (primary outcome); serious or nonserious e
82                                  One serious adverse event (transient atrial fibrillation) occurred i
83  from mechanical ventilation is viewed as an adverse event in ICUs.
84                      The most common serious adverse event in the active surveillance group was myoca
85 3 patients) was the most frequently reported adverse event in the alternative ACT group.
86                                              Adverse event incidences in the 24-week placebo-controll
87                        In these patients, no adverse event occurred when clinical pathways were corre
88 ondary end points included anatomic patency, adverse event rate, and return to operating room within
89 t treatments were not associated with higher adverse event rates than placebo.
90             The Food and Drug Administration Adverse Event Reporting System (FAERS) remains the prima
91                                          One adverse event unrelated to study devices occurred during
92 , whereas the most common non-haematological adverse event was hypokalaemia (25 [17%] of 147 vs 22 [1
93                              The most common adverse event was pain related to surgical incision or p
94 ed antitoxin (n = 193), 23 (12%) reported an adverse event, including rash, fever, serum sickness, an
95  to high-frequency hearing loss, an expected adverse event, was documented in all participants.
96 370 patients had a serious treatment-related adverse event.
97 , and no participants withdrew because of an adverse event.
98 -101 reported at least one treatment-related adverse event.
99                              Frequent severe adverse events (>4% difference from placebo) were diarrh
100 dies reported low rates of death and serious adverse events (0% to 1.25%) in nontransported patients
101                                 Before ASCT, adverse events (AEs) occurred in 98% of patients, mostly
102                       Daily temperatures and adverse events (AEs) were recorded days 1 to 42 postvacc
103                     Safety measures included adverse events (AEs), clinical laboratory tests, vital s
104                                   Grade >/=3 adverse events (AEs; >5%) included anemia, pneumonia, an
105 the placebo group; the most frequent serious adverse events (affecting >/=2% of patients) were elevat
106                            Treatment-related adverse events (any grade) prompted treatment discontinu
107                                              Adverse events (eg, lethargy, diarrhoea, rash, and nause
108            23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneu
109 even patients (61%) experienced drug-related adverse events (mostly grade 1-2); none discontinued tre
110  and one patient died from treatment-related adverse events (myositis in addition to grade 3 thyroidi
111                                      Serious adverse events (regardless of relation to study treatmen
112  primary outcomes were treatment failure and adverse events 14 days after diagnosis.
113 ney, leading to dose-limiting toxicities and adverse events affecting quality of life.
114            The most common treatment-related adverse events among the 54 patients were hypercholester
115     The primary outcome was the incidence of adverse events among vaccine and placebo recipients thro
116 hic angiography and strongly associated with adverse events among women.
117 al, body region scanned, type, dose, related adverse events and route of administration of sedatives
118 ATION: Despite an increase in haematological adverse events and second primary malignancies, lenalido
119                                              Adverse events are defined with Valve Academic Research
120 370 patients died from non-treatment-related adverse events associated with death, and one patient di
121                                 However, the adverse events associated with smoking limit its clinica
122                             No other serious adverse events attributable to angiotensin II were repor
123                                              Adverse events attributable to PHS cost an additional $6
124 arge differences in risk of systemic serious adverse events between these two anti-VEGF drugs; i.e.,
125 n in-hospital AKI and risk of post-discharge adverse events by AKIN stage.
126                                              Adverse events comprised CVD death, myocardial infarctio
127 tudy drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation an
128 pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two
129                           Rates of grade 3-4 adverse events did not differ among regimens (P = .37).
130                          Overall and serious adverse events did not differ between the flecainide and
131                  The overall rate of serious adverse events did not differ between treatment groups,
132 er, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the
133                      The annual frequency of adverse events did not occur more frequently with cumula
134               Incidence of treatment-related adverse events did not seem to be associated with dose a
135                                There were no adverse events either immediately or at 2-week follow-up
136  the transition from desired drug effects to adverse events following administration of either therap
137                                       Common adverse events in patients treated at the MTD (n = 57) i
138 febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubicin and
139 ived doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine and
140                                  We recorded adverse events in ten (34%) of 29 patients given twice-w
141                                       Ocular adverse events in the aflibercept group included 4 parti
142  than 10 mm Hg greater than baseline; ocular adverse events in the bevacizumab group included 1 parti
143                 The most frequently reported adverse events in the brexanolone group were dizziness (
144                             Exercise-related adverse events included musculoskeletal injuries.
145     A variety of dermatologic immune-related adverse events including maculopapular eruption, licheno
146                                 Drug-related adverse events occurred in 130 (24%) of 531 participants
147                                        Minor adverse events occurred in 22% of patients in the contro
148                         Drug-related serious adverse events occurred in 28 (38%) of 74 patients.
149                                 Five serious adverse events occurred in 4 cases (15%), including pulm
150                                              Adverse events occurred in 51 (48%) of CGM participants
151 s, and only grade 1 (mild) local or systemic adverse events occurred in both groups.
152                                Eight serious adverse events occurred in each group.
153 een treatment groups, although some specific adverse events occurred more often in the intensive grou
154                                           No adverse events occurred.
155                                      Serious adverse events occurring in 5% or more of patients were
156                                      Serious adverse events occurring in more than two patients inclu
157 ociated with a higher risk of the well-known adverse events of fever, rash, and convulsions within th
158                              The most common adverse events of grade 3 or higher during treatment wer
159                                              Adverse events of grade 3 or higher were reported in 87%
160                              The most common adverse events of grade 3 or worse severity were anaemia
161                        Trial withdrawals and adverse events of rash, dizziness, and dental discolorat
162                        There were no serious adverse events or discontinuations due to adverse events
163 significant differences in local or systemic adverse events or laboratory abnormalities between the P
164 s, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27 [1
165                              The most common adverse events reported in the re-treatment ACT group we
166     The most common grade 3-4 haematological adverse events reported, irrespective of attribution, we
167 [11.1%]) or placebo (32 of 255 [12.5%]); all adverse events resolved without sequelae.
168                      The most common serious adverse events that occurred through week 24 were anaemi
169 ched for studies in which rates of immediate adverse events to GBCAs were reported.
170 ed in phase 3 trials), the most common local adverse events versus placebo within the first 14 days w
171 tients who discontinued treatment because of adverse events was low (range, 0%-1%).
172                    Incidence and severity of adverse events was mostly similar between groups except
173                                 Incidence of adverse events was similar for alirocumab versus control
174                                 Incidence of adverse events was similar in all groups (43 [88%] of 49
175                                The number of adverse events was similar regardless of immunisation st
176                      The most common serious adverse events were anaemia (eight [4%]), upper gastroin
177                                              Adverse events were attributable to 23 (5%) deaths in th
178                                              Adverse events were common with medications but not with
179                                              Adverse events were defined as fatal or nonfatal aortic
180 he most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of 488 patients
181                                      Serious adverse events were experienced by 35 (18%) patients in
182                            Treatment-related adverse events were generally grade 1 or 2 in severity.
183                                              Adverse events were generally mild (</= grade 2), with d
184                             Thirteen serious adverse events were identified among recipients of HRV,
185                              The most common adverse events were infective pulmonary exacerbations, c
186           The most common isatuximab-related adverse events were infusion-associated reactions (IARs)
187                                      Data on adverse events were limited, but suggested an increased
188                                      All the adverse events were mild or moderate in severity.
189                                              Adverse events were more frequent with clindamycin (58 o
190                                              Adverse events were more frequent with tofacitinib than
191                                Deaths due to adverse events were observed in 27 (12%) patients in the
192        Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (1
193                                              Adverse events were rarely reported.
194                                    No severe adverse events were recorded.
195                                              Adverse events were reported as expected and were simila
196               Grade 3 to 4 treatment-related adverse events were reported in 38.3% and 61.7% of the p
197                                      Serious adverse events were reported in 56 (58%) eltrombopag-tre
198                                      Serious adverse events were reported in 64 (22%) of 288 patients
199                    No severe vaccine-related adverse events were reported.
200                                         Most adverse events were respiratory, and in some patients it
201                                              Adverse events were similar between the subgroups.
202                           The rates of renal adverse events were similar in the liraglutide group and
203                              The most common adverse events were skin reactions occurring in 49 (48%)
204   The most frequently observed grade 3 and 4 adverse events were transaminase increases (40% alanine
205                    The most common grade 3-4 adverse events with a suspected association with long-ac
206                                      Serious adverse events within 12 months after injection were see
207 nths, hemodialysis- and chemotherapy-related adverse events, and death.
208 r 92% of the 48 hours cooling period without adverse events, and was lower than the controls (34.35 d
209 of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did not dif
210          26 (39%) of 44 patients had grade 3 adverse events, but no grade 4 events were reported.
211  secondary objectives included evaluation of adverse events, changes in sexual quality of life using
212  outcome mainly relies on the declaration of adverse events, identification of their predictors, self
213 nd recognising, responding to and disclosing adverse events, including errors and near misses.
214       Seven (44%) of 16 patients had serious adverse events, most of which were related to the underl
215                                 Frequency of adverse events, mostly mild self-limited joint and back
216 recurrence or new breast cancer, intolerable adverse events, or consent withdrawal occurred.
217  occurred because of adverse events, serious adverse events, or deaths in patients who received lanad
218                                      Rate of adverse events, quality of life, and patient satisfactio
219                The three most common serious adverse events, representing 111 (39%) of all 285 seriou
220      No discontinuations occurred because of adverse events, serious adverse events, or deaths in pat
221 is needed to optimize its dosing to minimize adverse events, such as peripheral neuropathy.
222          Safety was assessed on the basis of adverse events, which were graded according to the Commo
223                         Major cardiovascular adverse events-free survival was worse in patients with
224                  The main safety measure was adverse events.
225 rding to the Common Terminology Criteria for Adverse Events.
226 ce of death, sudden death, and other cardiac adverse events.
227 mal peak flow, antibiotic use, or nonserious adverse events.
228 us adverse events or discontinuations due to adverse events.
229 fety assessments included treatment-emergent adverse events.
230 crease in cardiovascular and cerebrovascular adverse events.
231 up discontinued the trial regimen because of adverse events.
232 ade 1-2); none discontinued treatment due to adverse events.
233 nt with oral morphine, with similar rates of adverse events.
234 perglycemia among the most common high grade adverse events.
235  the intervention was high and there were no adverse events.
236 creased risk of complicated appendicitis and adverse events.
237               RCE was well tolerated with no adverse events.Twice daily RCE intake over 1 y potently
238             Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group, t
239                      Nine patients died from adverse events; five of these deaths were judged to be r
240                 12 patients reported serious adverse events; haemolysis and pyrexia were the most com
241         Two (1%) of 166 patients had serious adverse events; neither were considered related to study
242 %) patients had 11 grade 3 treatment-related adverse events; no single event occurred in more than on
243    Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and
244                                              Adverse experiences in childhood and adolescence, define
245 V) infection in pregnancy is associated with adverse fetal outcomes, such as microcephaly and other c
246 nancy was associated with the lowest risk of adverse fetal outcomes.
247 was the most frequently reported CXL-related adverse finding.
248 cimimetic could improve adherence and reduce adverse gastrointestinal effects.
249 e efficiency of targeted mutagenesis and the adverse generation of off-target mutations vary greatly
250 S) enrolled in the MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site a
251 stent relationship between aneurysm size and adverse HCM-related events.
252 s estrogenic activity and is associated with adverse health effects in humans and wildlife.
253 the troposphere, understanding mechanisms of adverse health effects through inhalation exposure is cr
254                                         Many adverse health outcomes are associated with obstructive
255 n disruptions are implicated in a variety of adverse health outcomes, including substance use disorde
256 eather events that have been associated with adverse health outcomes.
257 plication which has short-term and long-term adverse health ramifications for both women and their ch
258  treated from 1990 to 1999), those reporting adverse health status did not decrease by treatment deca
259                               No toxicity or adverse immune consequences of vector administration are
260 ovide vital information on the likelihood of adverse impacts during extreme ENSO events.
261 orically been associated with a high risk of adverse ischemic events, but there is a paucity of conte
262 ed with a considerably higher risk of 2-year adverse ischemic events, with HPR conferring similar ris
263  Certain variants may moderate the effect of adverse life events on the risk of GAD.
264 oved infarct size, LV ejection fraction, and adverse LV remodeling, changes associated with decreased
265 tment was associated with the lowest risk of adverse maternal outcomes, whereas the use of LMWH throu
266 ine's antidepressant efficacy, suggesting an adverse metabolic state.
267 tenuated strains, can still show substantial adverse or lethal actions in the brain.
268 n during 2013-14 influenza season attenuated adverse outcome among adults that were hospitalized with
269  associated with increased risk of composite adverse outcome independently of other risk factors.
270 g the first year of therapy, associated with adverse outcome.
271 ERT promoter mutations alone did not predict adverse outcomes (P = 0.50), but the presence of TERT pr
272 o prevent acute kidney injury and associated adverse outcomes after angiography without definitive ev
273 inical animal testing often fails to predict adverse outcomes arising from sequential, multi-organ me
274 harm and violent offending, respectively, as adverse outcomes at ages 15-35 years.
275  (MIDP) and identify actual risk factors for adverse outcomes compared with open distal pancreatectom
276 e in the volume-outcome model, risk-adjusted adverse outcomes declined, including mortality (3.57% to
277 ) and cardiac troponin I are associated with adverse outcomes in stable kidney transplant recipients.
278 low hemoglobin concentrations, the link with adverse outcomes is more evident when hemoglobin concent
279 rs are serious, avoidable, costly and common adverse outcomes of healthcare.
280 sed exposure might translate to sex-specific adverse outcomes such as behavioral deficits is a possib
281       We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and
282  sports participation may be associated with adverse outcomes, particularly at the elite level.
283 ronic kidney disease and are associated with adverse outcomes.
284 ent hyperglycemia is common and is linked to adverse patient outcomes.
285 elective hernia repair at increased risk for adverse postoperative events.
286  Panic disorder and GAD do not contribute to adverse pregnancy complications.
287 urning of biomass fuels has been linked with adverse pregnancy outcomes such as low birth weight, sti
288 increases globally, monitoring for potential adverse pregnancy outcomes will be crucial.
289 d complex disease that is associated with an adverse prognosis.
290 lerated the PET/MRI examination well, and no adverse reactions to (18)F-FTC-146 were reported.
291                                              Adverse reactions to oral azoles, drug interactions, and
292 lly respond to the desensitization protocol, adverse reactions were minor and responded to treatment
293 mal necrolysis (SJS/TEN) are rare but severe adverse reactions with high mortality.
294 broblast-specific Smad3 loss had accentuated adverse remodeling after reperfused infarction and exhib
295 ritis or nongonococcal urethritis in men and adverse reproductive sequelae in women-for example, cerv
296                             The incidence of adverse sedation outcomes varied significantly with type
297         In adults, high blood pressure (BP), adverse serum lipids, and smoking associate with cogniti
298 e serious problem of drug resistance and the adverse side effect profiles of many TB drugs, further i
299 ents to reduce the risk of radiation-related adverse systemic effects.
300 A could be safely used as an antidote during adverse therapeutic modulation of hemostasis.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top